Item 7.01 Regulation FD Disclosure.
On June 2, 2021, Wave Life Sciences Ltd. (the “Company”) issued a press release
announcing the first in vivo data from the Company’s ADAR editing discovery
program for alpha-1 antitrypsin deficiency (“AATD”). A copy of the press release
is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
From time to time, the Company presents and/or distributes slides and
presentations to the investment community to provide updates and summaries of
its business. On June 2, 2021, the Company updated its corporate presentation to
include the first in vivo data from the Company’s ADAR editing discovery program
for AATD. The presentation is available on the “For Investors & Media” section
of the Company’s website at http://ir.wavelifesciences.com/ and is furnished as
Exhibit 99.2 to this Current Report on Form 8-K.
The information in this Item 7.01 is being furnished and shall not be deemed
“filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as
amended (the “Exchange Act”), or otherwise subject to the liabilities of that
Section, nor shall it be deemed incorporated by reference into any registration
statement or other filing under the Securities Act of 1933, as amended, or the
Exchange Act, except as shall be expressly set forth by specific reference in
Item 9.01 Financial Statements and Exhibits.
The following exhibits relating to Item 7.01 are furnished and not filed:
Exhibit No. Description 99.1 Press Release issued by Wave Life Sciences Ltd. dated June 2, 2021 99.2 Corporate Presentation of Wave Life Sciences Ltd. dated June 2, 2021 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
© Edgar Online, source Glimpses